vTv Therapeutics Inc (VTVT): Price to Sales

Corporate company logo of vTv Therapeutics Inc. (VTVT)

vTv Therapeutics Inc. (VTVT) focuses on bringing TTP399 to market for the treatment of diabetes and psoriasis. The molecule development process is accelerated by AI and synthesis automation. The company's P/S ratio dynamics reflect the current market valuation, where 1.90 captures the value of this parameter. Growth prospects depend on the successful completion of final clinical trials with the support of external investors.

vTv Therapeutics Inc - VTVT P/S Multiple (period 07/04/2022 - 11/17/2026)

Metric breakdowns and analytics for vTv Therapeutics, Inc. (VTVT)

- current price and projected stock value:
- stock exchange capitalization data:
Summary company analytics:vtvtherapeutics.com VTVT
Core merchandise of vTv Therapeutics

The high pricing power potential of vTv Therapeutics Inc. (VTVT) within the inelastic demand segment of diabetic patients drives the asset's investment attractiveness. The price-to-sales ratio dynamics visualize the market valuation of every dollar of sales through the relationship between market capitalization and revenue. This metric allows for the determination of the premium paid for future revenues from the sale of the unique drug Govorestat. Trend analysis helps balance the risk of an overbought asset against the probability of missed opportunity.